Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

BACKGROUND: The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity. METHODS AND FINDINGS: In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to receive vaccine strengths of 5 or 10 μg/dose or place...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansarifar, Akram, Farahani, Ramin Hamidi, Rahjerdi, Ahmad Karimi, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Gholami, Fatemeh, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Azin, Hajar Mehr, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Poor, Ali Khodaei, Bakhshande, Hooman, Taghva, Zahra, Nia, Mohammad Karimi, Dodaran, Masoud Solaymani, Foroughizadeh, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628354/
https://www.ncbi.nlm.nih.gov/pubmed/37941802
http://dx.doi.org/10.1016/j.jvacx.2023.100401

Ejemplares similares

Ejemplares similares